Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Zephyr Venture Partners is a venture capital firm located in the San Francisco / Redwood City area, established to invest in and build early-stage biotechnology companies. The firm operates both as a traditional investor and as a company builder, incubating new ventures that align with its investment thesis. Zephyr emphasizes scale-invariant scientific insights, which are discoveries that maintain their validity and commercial relevance across different scales, from bench research to market application.
Currently, Zephyr Venture Partners manages a portfolio of five notable companies and has a team of six members. The firm focuses exclusively on biotechnology, targeting innovative solutions that can transition effectively from research to commercial viability. This dual approach of investing and incubating allows Zephyr to play a significant role in the development of its portfolio companies.
Zephyr Venture Partners specializes in biotechnology, with a clear focus on companies that leverage scale-invariant scientific insights. This investment strategy ensures that the underlying science remains valid from early research through to commercial application. The firm targets early-stage companies, particularly in the seed and incubation phases, allowing it to engage deeply with the ventures it supports.
The firm seeks to back innovative solutions that can effectively transition from research to market, particularly in deeptech categories within life sciences and regulated healthcare markets. Zephyr's investment thesis revolves around identifying compelling scientific insights that can lead to transformative advancements in biotechnology. This focus on scale-invariant insights positions Zephyr as a unique player in the venture capital landscape.
Zephyr Venture Partners has a concentrated portfolio of five companies, each aligned with its focus on biotechnology and scale-invariant scientific insights. The notable portfolio companies include:
Gokul Kannan: Gokul is a key member of the Zephyr team, bringing expertise in biotechnology and investment strategies. His background includes experience in both scientific research and venture capital.
Praneeth Goli: Praneeth contributes to Zephyr's investment decisions with a strong foundation in life sciences and technology. His previous roles have involved working with early-stage biotech companies.
Ehsan Agahi: Ehsan has a background in genomics and AI, providing valuable insights into the firm's portfolio companies focused on these areas.
Mikail Jaffer: Mikail's experience in venture capital and biotechnology enhances Zephyr's ability to identify promising investment opportunities.
Felix Majewski: Felix brings a unique perspective to the team, with expertise in both scientific research and business development within the biotech sector.
Basel Karim: Basel's background in investment and biotechnology supports Zephyr's mission to back innovative companies in the life sciences.
To pitch to Zephyr Venture Partners, founders should send an email to info@zephyrvp.com. The pitch deck should include a clear description of the scientific insight, the problem being addressed, and the potential market opportunity. Founders are encouraged to provide details on their team and any preliminary research or data supporting their claims.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions are preferred, but cold emails are also accepted if they are well-crafted and concise.
As of March 2026, Zephyr Venture Partners continues to focus on its investment strategy in biotechnology, emphasizing scale-invariant scientific insights. The firm has recently incubated two companies, Samata Therapeutics and Ashvattha Therapeutics, both of which are making strides in their respective fields.
Zephyr's portfolio remains concentrated with five notable companies, including FDNA and Aether Biomachines, which are recognized leaders in genomics and AI diagnostics, and AI-driven protein design, respectively. The firm is actively seeking new opportunities to expand its portfolio in the biotechnology sector.
What are Zephyr Venture Partners' investment criteria?
Zephyr Venture Partners focuses exclusively on biotechnology companies that leverage scale-invariant scientific insights. The firm looks for compelling scientific insights that can transition from early research to commercial application.
How can I apply or pitch to Zephyr Venture Partners?
Founders can reach out via email at info@zephyrvp.com to pitch their ideas or apply for funding. A clear articulation of the scientific insight and its commercial potential is crucial.
What makes Zephyr Venture Partners different from other VC firms?
Zephyr operates both as a traditional investor and as a company builder, allowing it to incubate new ventures. This dual approach enables deeper engagement with portfolio companies and a focus on scale-invariant scientific insights.
What is the geographic scope of Zephyr's investments?
Zephyr Venture Partners is based in the San Francisco / Redwood City area and primarily invests in biotechnology companies within the United States, particularly those that align with its investment thesis.
What is the typical check size for investments?
While specific check sizes are not disclosed, Zephyr focuses on early-stage investments, which typically involve seed funding and incubation support for new ventures.
What kind of post-investment involvement does Zephyr have?
Zephyr Venture Partners provides not only capital but also strategic guidance and support to its portfolio companies, helping them navigate the complexities of the biotechnology landscape.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.